Name: Juvmo (tavapadon) in Parkinson's disease: Effects of tavapadon on other drugs
Published: 2026-09-27T21:44:59-04:00

Product information and disease description Product description Product information Drug/Drug, drug/disease interactions

Effects of tavapadon on other drugs

5 evidence topics · 1 source

Predicted clinically relevant interactions

“Tavapadon is predicted to cause clinically relevant induction of CYP3A, inhibition of CYP2C8, and BCRP [see Drug Interactions (7.2)].” (opens the prescribing information at this quote)

CYP3A substrates

“Consider a dose modification of sensitive CYP3A substrates or CYP3A substrates where minimal concentration changes may lead to loss of efficacy, as clinically appropriate, when initiating or discontinuing JUVMO.” (opens the prescribing information at this quote)
“JUVMO is an inducer of CYP3A [see Clinical Pharmacology (12.3)]. Concomitant use of JUVMO may decrease the concentrations of CYP3A substrates.” (opens the prescribing information at this quote)

CYP2C8 substrates

“Consider a dosage reduction of sensitive CYP2C8 substrates or CYP2C8 substrates where minimal concentration changes may increase the risk of severe adverse reactions, as clinically appropriate, when concomitantly used with JUVMO.” (opens the prescribing information at this quote)
“JUVMO is an inhibitor of CYP2C8 [see Clinical Pharmacology (12.3)]. Concomitant use of JUVMO may increase the plasma concentrations of CYP2C8 substrates.” (opens the prescribing information at this quote)

BCRP substrates

“Consider a dosage reduction of BCRP substrates, as clinically appropriate, when concomitantly used with JUVMO.” (opens the prescribing information at this quote)
“JUVMO is an inhibitor of efflux transporter BCRP [see Clinical Pharmacology (12.3)]. Concomitant use of JUVMO may increase the exposure of BCRP substrates.” (opens the prescribing information at this quote)

In vitro inhibition and induction profile

“Tavapadon is a time-dependent inhibitor of CYP2C8. Tavapadon and M4 did not demonstrate time-dependent inhibition of CYP1A2, 2B6, 2C9, 2C19, 2D6, or 3A4.” (opens the prescribing information at this quote)
“Tavapadon and M4 are inducers of CYP3A, but are not inducers of CYP1A2 or CYP2B6.” (opens the prescribing information at this quote)
“UDP-Glucuronosyltransferase (UGT): Tavapadon is an inhibitor of UGT1A9 but is not expected to result in clinically significant drug interactions.” (opens the prescribing information at this quote)
“Tavapadon inhibits BCRP, but not P-gp, OATP1B1, OATP1B3, OCT1, OCT2, OAT1, or OAT3.” (opens the prescribing information at this quote)